Business
BioElectronics Announces Publication of Breakthrough Clinical Study for Drug-free Treatment of Chronic Osteoarthritis
BioElectronics Announces Publication of Breakthrough Clinical Study for Drug-free Treatment of Chronic Osteoarthritis.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n\n\n\nBioElectronics Announces Publication of Breakthrough Clinical Study for Drug-free Treatment of Chronic Osteoarthritis\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nBioElectronics Announces Publication of Breakthrough Clinical Study for Drug-free Treatment of Chronic Osteoarthritis\nPR Newswire\nFREDERICK, Md., Jan. 5, 2016\n\n\n\nFREDERICK, Md., Jan. 5, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices announced publication of a clinical study demonstrating the efficacy of ActiPatch® Therapy for knee osteoarthritis. This study further validates the positive effects of negating chronic pain central sensitization1 by ActiPatch® noninvasive neuromodulation therapy. The technology is affordable, effective, and a safe alternative to prescription opioid therapy that is drastically needed in the US and by the 1.5 billion worldwide chronic pain sufferers.  \n\nOxford University Press on behalf of the British Society of Rheumatology published the study in their journal Rheumatology (www.rheumatology.oxfordjournals.org). The clinical study was an independently conducted, double blind, placebo-controlled, randomized clinical trial. There was a reported statistically significant reduction in pain and a significant improvement in the WOMAC2 physical assessments. In addition, patients in the treatment group displayed a reduced use of NSAIDs3 and reported an improvement in their quality of life compared to the placebo group. \n\n\"The data from this comprehensive clinical study shows ActiPatch's ability to improve the management of osteoarthritis of the knee,\" said Ian Rawe, Ph.D., Director of Clinical Research. \"We sincerely thank the clinical scientists who conducted this study led by Dr. Gianluca Bagnato, Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Messina, Italy.\"\n\nThis study further demonstrates the noninvasive neuromodulation of ActiPatch® Therapy as the pain pressure threshold increased. This data along with positive treatment of chroni...